Management of metastatic clear cell renal cell carcinoma: ASCO guideline
WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
[HTML][HTML] First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting …
Background Immunotherapy represents the standard of care in the first-line treatment of
advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high programmed …
advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high programmed …
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: results of an …
Background The combination of platinum-based chemotherapy with immune-checkpoint
inhibitors (ICIs) is a standard of care option in the front-line treatment of advanced non-small …
inhibitors (ICIs) is a standard of care option in the front-line treatment of advanced non-small …
[HTML][HTML] Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era
NJ Shah, SD Sura, R Shinde, J Shi, PK Singhal… - European Urology Open …, 2023 - Elsevier
Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …
Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta …
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung
cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these …
cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these …
[HTML][HTML] CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic …
Background There are limited data evaluating the activity of cabozantinib (CABO) as second
line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno …
line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno …
Pembrolizumab for all
The current approval indications for pembrolizumab are complex, reflecting the inclusion
criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use …
criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use …
[HTML][HTML] Advanced non-small-cell lung cancer: how to manage non-oncogene disease
The therapeutic approach to patients affected by advanced non-small-cell lung cancer
(NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new …
(NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new …
[HTML][HTML] Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors
DE Meyers, M Pasternak, S Dolter, HAI Grosjean… - JTO Clinical and …, 2023 - Elsevier
Introduction Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC
are difficult to extrapolate to real-world practice given the exclusion of patients with poor …
are difficult to extrapolate to real-world practice given the exclusion of patients with poor …
Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of …
H Ishihara, Y Nemoto, K Nakamura, H Tachibana… - Targeted Oncology, 2023 - Springer
Background Clinical trials have demonstrated the superior efficacy of immune checkpoint
inhibitor (ICI)-based combination therapy over sunitinib, a multi-target tyrosine kinase …
inhibitor (ICI)-based combination therapy over sunitinib, a multi-target tyrosine kinase …